| Literature DB >> 12361480 |
W P Olszynski1, G Ioannidis, R J Sebaldt, D A Hanley, A Petrie, J P Brown, R G Josse, T M Murray, C H Goldsmith, G F Stephenson, A Papaioannou, J D Adachi.
Abstract
BACKGROUND: The identification of new methods of evaluating patients with osteoporotic fracture should focus on their usefulness in clinical situations such that they are easily measured and applicable to all patients. Thus, the purpose of this study was to examine the association between iliocostal distance and vertebral and non-vertebral fractures in patients seen in a clinical setting.Entities:
Year: 2002 PMID: 12361480 PMCID: PMC130045 DOI: 10.1186/1471-2474-3-22
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Figure 1Measurement Technique for Iliocostal Distance. Represents iliocostal distance. Iliocostal distance was defined as the number of cm between the costal margin and the pelvic ridge of a patient, measured in the midaxillary line.
Baseline characteristics of women and men*
| Women n = 508 | Men n = 41 | |
| Age-years (SD) | 61.5 (11.3) | 57.8 (12.4) |
| Height-cm (SD) | 160.8 (9.6) | 174.8 (18.3) |
| Weight-kg (SD) | 67.8 (14.4) | 86.2 (22.0) |
| Iliocostal distance-cm (SD) | 4.2 (1.6) | 4.6 (1.5) |
| Menopausal status-#post/#pre | 424/78 | NA |
| Age at menopause-years (SD) | 47.3 (6.8) | NA |
| Lumbar spine BMD-g/cm2 (SD) | 0.867 (0.165) | 0.918 (0.165) |
| Femoral neck BMD-g/cm2 (SD) | 0.664 (0.112) | 0.713 (0.124) |
| Trochanter BMD-g/cm2 (SD) | 0.608 (0.107) | 0.676 (0.123) |
| Ward's triangle BMD-g/cm2 (SD) | 0.483 (0.133) | 0.471 (0.155) |
| Currently smoking-# | 64 | 6 |
| Family history of fracture-# | 122 | 12 |
| Alcohol-beverages/week (SD) | 1.4 (3.0) | 5.5 (8.7) |
| Number of falls – min to max | 0–12 | 0–4 |
| Calcium intake-mg/d (SD) | 539.0 (435.9) | 553.5 (375.4) |
| Exercise-minutes/week (SD) | 166.7 (165.9) | 187.9 (293.0) |
| Etidronate use-# (%) | 50 (9.8) | 3 (7.3) |
| Alendronate use-# (%) | 41 (8.1) | 7 (17.1) |
| Fluoride use-# (%) | 2 (0.4) | 0 (0.0) |
| Raloxifene use-# (%) | 9 (1.8) | 0 (0.0) |
| Hormone replacement use-# (%) | 146 (28.7) | 0 (0.0) |
| Corticosteroids use-# (%) | 77 (15.2) | 8 (19.5) |
| Calcium supplement use-# (%) | 366 (72.0) | 16 (39.0) |
| Vitamin D supplement use-# (%) | 173 (34.1) | 10 (24.4) |
| Lung diseasea-# (%) | 59 (11.6) | 3 (7.3) |
| Liver diseaseb-# (%) | 13 (2.6) | 2 (4.9) |
| Thyroid diseasec-# (%) | 69 (13.6) | 0 (0.0) |
| Cancerd-# (%) | 14 (2.8) | 0 (0.0) |
| Visual impairment-# (%) | 51 (10.0) | 2 (4.9) |
| Osteoporosis-# (%) | 187 (36.8) | 13 (31.7) |
| Inflammatory bowel disease-# (%) | 15 (3.0) | 5 (12.2) |
| Epilepsy-# (%) | 7 (1.4) | 2 (4.9) |
| Coronary disease-# (%) | 12 (2.4) | 1 (2.4) |
| Cerebrovascular disease-# (%) | 19 (3.7) | 1 (2.4) |
| Rheumatoid arthritis-# (%) | 5 (1.0) | 0 (0.0) |
| Diabetes-# (%) | 18 (3.5) | 0 (0.0) |
| Kidney failure-# (%) | 24 (4.7) | 0 (0.0) |
* BMD= bone mineral density; SD= standard deviation; # = number of patients; %=percent of patients; NA= not applicable. a Lung disease includes asthma, chronic bronchitis and other lung diseases. b Liver disease includes cirrhosis, hepatitis and cholangitis. c Thyroid disease includes hyper, hypo, nodule, and other. d Cancer includes breast, ovaries, cervix, uterus and colon.
Iliocostal distance and the number of vertebral and non-vertebral fractures in women and men
| Women | Men | |
| Vertebral Factures | ||
| 0* | 4.53 (1.52) | 4.77 (1.54) |
| 1 | 3.90 (1.73) | 4.54 (1.57) |
| 2 | 3.79 (1.75) | 4.00 (2.00) |
| 3 | 2.91 (1.41) | 4.00 (0.00) |
| 4+ | 3.75 (2.06) | 3.00 (1.41) |
* Indicates patients without vertebral or non-vertebral fractures.
Univariate parameter coefficient estimates and P-values for the association between risk factors and the number of vertebral and non-vertebral fractures in women
| No. Vertebral fractures | No. Non-Vertebral Fractures | |||
| Coefficient | P-value | Coefficient | P-value | |
| Age | 0.034 | <0.001 | 0.018 | <0.001 |
| Height | -0.012 | 0.083 | 0.004 | 0.454 |
| Weight | -0.001 | 0.768 | 0.002 | 0.534 |
| Iliocostal distance | -0.271 | <0.001 | -0.115 | <0.001 |
| Menopausal status | 0.516 | 0.003 | 0.305 | 0.015 |
| Age at menopause | 0.001 | 0.917 | -0.006 | 0.405 |
| Lumbar spine BMD | -0.813 | 0.048 | -0.722 | 0.026 |
| Femoral neck BMD | -3.069 | <0.001 | -1.901 | <0.001 |
| Trochanter BMD | -3.381 | <0.001 | -2.415 | <0.001 |
| Ward's triangle BMD | -2.928 | <0.001 | -1.951 | <0.001 |
| Prevalent vertebral fractures | NA | 0.310 | 0.002 | |
| Prevalent non-vertebral fractures | 0.391 | 0.003 | NA | |
| Currently smoking | 0.018 | 0.759 | 0.049 | 0.258 |
| Family history of fracture | -0.158 | 0.305 | 0.121 | 0.272 |
| Alcohol-beverages/week | -0.013 | 0.529 | -0.012 | 0.435 |
| No. of falls | -0.004 | 0.935 | 0.079 | 0.017 |
| Calcium intake | -0.000 | 0.499 | 0.000 | 0.536 |
| Exercise | -0.000 | 0.248 | -0.000 | 0.895 |
| Etidronate use | 0.315 | 0.003 | 0.188 | 0.014 |
| Alendronate use | 0.250 | 0.009 | 0.062 | 0.366 |
| Fluoride use | 0.392 | 0.541 | 0.843 | 0.067 |
| Raloxifene use | -0.053 | 0.807 | 0.167 | 0.280 |
| Hormone replacement use | -0.069 | 0.551 | -0.001 | 0.992 |
| Corticosteroids use | 0.113 | 0.308 | -0.046 | 0.564 |
| Calcium supplement use | 0.302 | 0.006 | 0.107 | 0.171 |
| Vitamin D supplement use | 0.147 | 0.115 | 0.094 | 0.163 |
| Lung diseasea | 0.223 | 0.264 | 0.334 | 0.020 |
| Liver diseaseb | -0.068 | 0.866 | -0.143 | 0.621 |
| Thyroid diseasec | -0.185 | 0.318 | 0.060 | 0.656 |
| Cancerd | 0.327 | 0.400 | 0.190 | 0.495 |
| Visual impairment | 0.136 | 0.526 | 0.174 | 0.258 |
| Osteoporosis | -0.109 | 0.409 | 0.002 | 0.982 |
| Inflammatory bowel disease | -0.634 | 0.091 | 0.618 | 0.022 |
| Epilepsy | 1.047 | 0.054 | -0.175 | 0.656 |
| Coronary disease | 0.582 | 0.164 | 0.401 | 0.174 |
| Cerebrovascular disease | 1.042 | 0.002 | 1.016 | <0.001 |
| Rheumatoid arthritis | 0.083 | 0.898 | 0.403 | 0.383 |
| Diabetes | 0.157 | 0.648 | 0.241 | 0.328 |
| Kidney failure | 0.115 | 0.700 | 0.200 | 0.352 |
* BMD= bone mineral density, NA= not available. a Lung disease includes asthma, chronic bronchitis and other lung diseases. b Liver disease includes cirrhosis, hepatitis and cholangitis. c Thyroid disease includes hyper, hypo, nodule, and other. d Cancer includes breast, ovaries, cervix, uterus and colon.
Univariate parameter coefficient estimates and P-values for the association between risk factors and the number of vertebral and non-vertebral fractures in men*
| No. Vertebral fractures | No. Non-Vertebral Fractures | |||
| Coefficient | P-value | Coefficient | P-value | |
| Age | 0.035 | 0.072 | -0.005 | 0.788 |
| Height | -0.034 | 0.010 | -0.017 | 0.164 |
| Weight | 0.007 | 0.523 | 0.015 | 0.155 |
| Iliocostal distance | -0.259 | 0.095 | -0.037 | 0.796 |
| Lumbar spine BMD | -2.360 | 0.174 | -0.399 | 0.779 |
| Femoral neck BMD | -1.378 | 0.511 | -0.106 | 0.953 |
| Trochanter BMD | -1.728 | 0.410 | -0.822 | 0.646 |
| Ward's triangle BMD | -2.138 | 0.196 | 0.275 | 0.846 |
| Prevalent vertebral fractures | NA | 0.396 | 0.361 | |
| Prevalent non-vertebral fractures | -0.090 | 0.851 | NA | |
| Currently smoking | 0.036 | 0.876 | 0.161 | 0.443 |
| Family history of fracture | -0.538 | 0.330 | -0.647 | 0.184 |
| Alcohol-beverages/week | -0.002 | 0.933 | 0.043 | 0.079 |
| No. of falls | 0.691 | 0.002 | 0.561 | 0.006 |
| Calcium intake-mg/d | 0.001 | 0.028 | 0.000 | 0.600 |
| Exercise-min/week | -0.000 | 0.683 | -0.001 | 0.484 |
| Etidronate use | 0.259 | 0.574 | -0.180 | 0.665 |
| Alendronate use | 0.589 | 0.038 | 0.036 | 0.891 |
| Fluoride use | NA | NA | ||
| Raloxifene use | NA | NA | ||
| Hormone replacement use | NA | NA | ||
| Corticosteroids use | -0.479 | 0.286 | 0.000 | 1.000 |
| Calcium supplement use | -0.014 | 0.972 | -0.370 | 0.279 |
| Vitamin D supplement use | 0.010 | 0.977 | 0.000 | 1.000 |
| Lung diseasea | -0.921 | 0.315 | 0.000 | 1.000 |
| Liver diseaseb | 1.205 | 0.276 | 1.051 | 0.292 |
| Thyroid diseasec | NA | NA | ||
| Cancerd | NA | NA | ||
| Visual impairment | -0.257 | 0.810 | 1.635 | 0.082 |
| Osteoporosis | 1.003 | 0.046 | 0.113 | 0.809 |
| Inflammatory bowel disease | -0.517 | 0.480 | 0.000 | 1.000 |
| Epilepsy | -0.897 | 0.419 | -1.051 | 0.292 |
| Coronary disease | -0.875 | 0.574 | 0.000 | 1.000 |
| Cerebrovascular disease | 3.225 | 0.033 | 3.075 | 0.024 |
| Rheumatoid arthritis | NA | NA | ||
| Diabetes | NA | NA | ||
| Kidney failure | NA | NA | ||
* BMD= bone mineral density, NA= not available. a Lung disease includes asthma, chronic bronchitis and other lung diseases. b Liver disease includes cirrhosis, hepatitis and cholangitis. c Thyroid disease includes hyper, hypo, nodule, and other. d Cancer includes breast, ovaries, cervix, uterus and colon.